KRAS突变对结直肠腺癌肝转移灶2-[18F]FDG PET摄取的影响
经部分容积效应校正和摄取时间变异性校正后,SURMAX与KRAS错义突变状态相关性最强(p≤0.001,ROC AUC为0.77和0.75)。
要点
- 部分容积效应校正和摄取时间校正可增强FDG PET识别KRAS突变的关联。
- 双校正后SURMAX区分KRAS错义突变与野生型的AUC达0.77和0.75。
- 平均特异度0.69、灵敏度0.85,提示FDG PET有潜力推断KRAS状态。
核心结论
- 应用所述校正后,2-[18F]FDG PET图像有潜力为结直肠腺癌肝转移的KRAS错义突变状态分配概率。
主要发现
- 对各病灶所有摄取指标应用部分容积效应校正、对SUR指标应用摄取时间变异性校正后,区分KRAS突变病例的Student t检验p值下降。
- 当两种校正均应用于SURMAX且将基因扩增患者与野生型归组时,相关性最强:p≤0.001;两种不同分割方法的ROC曲线下面积分别为0.77和0.75,平均特异度0.69、灵敏度0.85。
关键数值与推荐
- SUV指标包括平均、峰值和最大SUV;SUR指标包括SURMEAN、SURPEAK和SURMAX,即肿瘤平均、峰值和最大摄取与扫描时平均血活度浓度的比值。
- 部分容积效应校正使用由不同直径体模球获得的冷壁校正对比恢复系数;摄取时间变异性校正基于肿瘤-血标准摄取比值(SUR)方法。
- KRAS错义突变与野生型(含基因扩增归组)区分时,双校正SURMAX的p≤0.001,ROC AUC为0.77和0.75,平均特异度0.69、灵敏度0.85。
临床怎么用
- 在结直肠腺癌肝转移中,可考虑对2-[18F]FDG PET摄取指标进行部分容积效应和摄取时间变异性校正后,辅助推断KRAS错义突变状态的概率。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Deriving individual tumor genomic characteristics from patient imaging analysis is desirable. We explore the predictive value of 2-[18F]FDG uptake with regard to the KRAS mutational status of colorectal adenocarcinoma liver metastases (CLM). METHODS: 2-[18F]FDG PET/CT images, surgical pathology and molecular diagnostic reports of 37 patients who underwent PET/CT-guided biopsy of CLM were reviewed under an IRB-approved retrospective research protocol. Sixty CLM in 39 interventional PET scans of the 37 patients were segmented using two different auto-segmentation tools implemented in different commercially available software packages. PET standard uptake values (SUV) were corrected for: (1) partial volume effect (PVE) using cold wall-corrected contrast recovery coefficients derived from phantom spheres with variable diameter and (2) variability of arterial tracer supply and variability of uptake time after injection until start of PET scan derived from the tumor-to-blood standard uptake ratio (SUR) approach. The correlations between the KRAS mutational status and the mean, peak and maximum SUV were investigated using Student's t test, Wilcoxon rank sum test with continuity correction, logistic regression and receiver operation characteristic (ROC) analysis. These correlation analyses were also performed for the ratios of the mean, peak and maximum tumor uptake to the mean blood activity concentration at the time of scan: SURMEAN, SURPEAK and SURMAX, respectively. RESULTS: Fifteen patients harbored KRAS missense mutations (KRAS+), while another 3 harbored KRAS gene amplification. For 31 lesions, the mutational status was derived from the PET/CT-guided biopsy. The Student's t test p values for separating KRAS mutant cases decreased after applying PVE correction to all uptake metrics of each lesion and when applying correction for uptake time variability to the SUR metrics. The observed correlations were strongest when both corrections were applied to SURMAX and when the patients harboring gene amplification were grouped with the wild type: p ≤ 0.001; ROC area under the curve = 0.77 and 0.75 for the two different segmentations, respectively, with a mean specificity of 0.69 and sensitivity of 0.85. CONCLUSION: The correlations observed after applying the described corrections show potential for assigning probabilities for the KRAS missense mutation status in CLM using 2-[18F]FDG PET images.
引用
- Popovic M, Talarico O, van den Hoff J, et al. KRAS mutation effects on the 2-[18F]FDG PET uptake of colorectal adenocarcinoma metastases in the liver. EJNMMI Res. 2020. PMID: 33226505. doi:10.1186/s13550-020-00707-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。